Patents by Inventor Aprile L. Pilon
Aprile L. Pilon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230241163Abstract: Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin and secretoglobin 1A1 (SCGB1A1), to reduce virus titers in the tissues of patients, particularly influenza, ebola, and coronavirus titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza, ebola, and coronavirus infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza, ebola, and coronavirus infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans.Type: ApplicationFiled: June 2, 2021Publication date: August 3, 2023Inventor: Aprile L. PILON-CLAYTON
-
Patent number: 11690893Abstract: SCGB-based preparations and methods to use these preparations to protect the glycocalyx in medical, veterinary, and cosmetic applications are provided. The secretoglobins (SCGBs) are a family of small secreted globular proteins present in all mammals and sharing conserved structure and thought to share similar immunomodulatory functions. Heparan sulfate proteoglycan proteins (HSPGs) are expressed on the outer membranes of cells and have carbohydrate side chains that, together, make up the glycocalyx. The glycocalyx is a protective layer surrounding all cells, acting as a filter regulating the passage of nutrients into the cell and modifying cell signaling by external factors. There are two major families of HSPGs including syndecans and glypicans, plus several other HSPGs in all mammals. SCGBs bind to, and interact with, HSPGs to further modulate cell signaling and cellular responses to external factors.Type: GrantFiled: December 2, 2019Date of Patent: July 4, 2023Inventors: Aprile L Pilon-Clayton, Melissa E. Winn
-
Patent number: 11512121Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.Type: GrantFiled: February 7, 2020Date of Patent: November 29, 2022Assignee: APC Research Assets, LLCInventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
-
Publication number: 20220054587Abstract: SCGB-based preparations and methods to use these preparations to protect the glycocalyx in medical, veterinary, and cosmetic applications are provided. The secretoglobins (SCGBs) are a family of small secreted globular proteins present in all mammals and sharing conserved structure and thought to share similar immunomodulatory functions. Heparan sulfate proteoglycan proteins (HSPGs) are expressed on the outer membranes of cells and have carbohydrate side chains that, together, make up the glycocalyx. The glycocalyx is a protective layer surrounding all cells, acting as a filter regulating the passage of nutrients into the cell and modifying cell signaling by external factors. There are two major families of HSPGs including syndecans and glypicans, plus several other HSPGs in all mammals. SCGBs bind to, and interact with, HSPGs to further modulate cell signaling and cellular responses to external factors.Type: ApplicationFiled: December 2, 2019Publication date: February 24, 2022Applicant: APC Research Assets LLCInventors: Aprile L PILON-CLAYTON, Melissa E. WINN
-
Publication number: 20210363203Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: ApplicationFiled: April 5, 2021Publication date: November 25, 2021Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariparkasha, Richard S. Clayton, Melissa E. Winn
-
Publication number: 20200325190Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: ApplicationFiled: June 9, 2020Publication date: October 15, 2020Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Publication number: 20200262878Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.Type: ApplicationFiled: February 7, 2020Publication date: August 20, 2020Inventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
-
Patent number: 10676513Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: GrantFiled: May 20, 2019Date of Patent: June 9, 2020Assignee: APC Research Assets, LLCInventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Patent number: 10556938Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.Type: GrantFiled: September 18, 2017Date of Patent: February 11, 2020Assignee: APC Research Assets, LLCInventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
-
Publication number: 20190337999Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: ApplicationFiled: May 20, 2019Publication date: November 7, 2019Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Patent number: 10294285Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: GrantFiled: July 17, 2016Date of Patent: May 21, 2019Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Publication number: 20180244735Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.Type: ApplicationFiled: September 18, 2017Publication date: August 30, 2018Inventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
-
Publication number: 20180125931Abstract: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.Type: ApplicationFiled: November 10, 2017Publication date: May 10, 2018Applicant: Therabron Therapeutics, Inc.Inventor: Aprile L. Pilon-Clayton
-
Patent number: 9844580Abstract: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.Type: GrantFiled: February 12, 2016Date of Patent: December 19, 2017Assignee: Therabron Therapeutics, Inc.Inventor: Aprile L. Pilon-Clayton
-
Patent number: 9765127Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.Type: GrantFiled: October 12, 2015Date of Patent: September 19, 2017Assignee: Therabron Therapeutics, Inc.Inventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
-
Publication number: 20160362462Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: ApplicationFiled: July 17, 2016Publication date: December 15, 2016Applicant: Therabron Therapeutics, Inc.Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Patent number: 9394349Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified CC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of CC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: GrantFiled: March 15, 2013Date of Patent: July 19, 2016Assignee: Therabron Therapeutics, Inc.Inventors: Aprile L. Pilon, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Publication number: 20160158315Abstract: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.Type: ApplicationFiled: February 12, 2016Publication date: June 9, 2016Applicant: Therabron Therapeutics, Inc.Inventor: Aprile L. Pilon
-
Publication number: 20160159870Abstract: Methods of synthetically producing, formulating and using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 are provided. Methods of using secretoglobins SCGB1A1, SCGB3A2, and SCGB3A1 as therapeutic agents to affect long term patient outcomes, such as preventing severe respiratory exacerbations of underlying conditions that require medical intervention, including hospitalization are provided. Methods of producing recombinant human secretoglobins, analytical methods, pharmaceutical compositions, and methods of use to prevent the long term sequelae of acute and chronic respiratory conditions are provided.Type: ApplicationFiled: October 12, 2015Publication date: June 9, 2016Inventors: Aprile L. Pilon, Melissa E. Winn, John K. Zehmer
-
Patent number: 9168285Abstract: Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza and filovirus titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza and ebola infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza and ebola infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans.Type: GrantFiled: February 16, 2015Date of Patent: October 27, 2015Assignee: THERABRON THERAPEUTICS, Inc.Inventor: Aprile L Pilon